Aggregated price index
Aggregated price index with volume information
Summary:
- Biotechnology stocks up 1.5% on average while median return up 1.5% in a day
- Biotechnology stocks down 0.6% on average while median return down 0.7% in a week
- Biotechnology stocks up 5.8% on average while median return up 4.6% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
Click on + to show price series and click on ticker for stock detail page
* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.
* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.
* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.
- 1M winners are : Winners for past month are $WVE 148.4%, $TPTX 124.7%, $COGT 120.7%, $OMER 91.7%, $KZR 91.2%
- 1M losers are : Losers for past month are $APLT -34.0%, $BIVI -41.3%, $ENOB -48.7%, $ATHA -64.1%, $ADXN -68.7%
- 1W winners are : Winners for past week are $IFRX 84.4%, $OMER 77.8%, $KZR 53.8%, $AGTC 26.4%, $EQ 24.1%
- 1W losers are : Losers for past week are $BIVI -22.5%, $CLDX -22.7%, $BNTC -24.2%, $HGEN -24.8%, $ENOB -42.0%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 28.5%, for the past 3 months is 29.4%
In the past month for a 5 days rolling window, the highest corrrelation is 56.0%, the lowest correlation is 9.3%, the latest correlation is 13.5%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 80.6% between AGIO and ALEC
The lowest correlation is -45.1% between ADXN and ALVR
Stock news
LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors a clear understanding of the Company’s pipelines. The results of this investigation verified key primary data for the Company’s HIV and cancer pipelines. The investigation also verified the primary data from an animal model with intravenous delivery of a potential treatment for COVID-19 that was
PARSIPPANY, N.J., July 01, 2022--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee.
Shares of the commercial-stage biopharma Aurinia Pharmaceuticals (NASDAQ: AUPH) rose by as much as 13.7% during Friday's trading session. This time around, Japanese drug manufacturer Otsuka Holdings is rumored to be considering a bid, according to a report posted on the subscription-based Betaville website and subsequently circulated on Twitter. Aurinia, for its part, has not commented on this takeover speculation.
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that, on June 30, 2022 the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is u
WALTHAM, Mass., July 01, 2022--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 50,000 ordinary shares of the Company. The option
SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued inducement grants of stock options to two new employees. Achieve’s Board of Directors approved the new employment inducement grants to purchase an aggregate of 15,000 shares of Ach